old news 201924 Sep 2020 22:18
ValiRx confirmed that Dr Rebecca Kristeleit was continuing with the study as chief investigator.
It said that to date, the results generated by the trial - aided by sizable analytical method developments - had shown that safe toxicological limits could be significantly elevated and applied to much higher levels in humans than was suggested by the preclinical studies.
The approval given to relax the restrictions previously applied to the trial would mean that a more effective use of VAL201 could be achieved with respect to concentration and timing, and regarding increased flexibility in the administration of the drug, the board explained